Shire's New Product Portfolio Delivers Strong Quarterly P...(folio will continueto deliver strong hig...)

Date:10/29/2008

folio will continue to deliver strong, high margin growth throughout 2009 and 2010 and provide the platform for future revenue and earnings growth. There are a number of variables that can impact the exact rate of erosion of ADDERALL XR's sales and we have contingency plans in place to cover these different outcomes. While we will continue to invest in the future growth drivers of the business, our discretionary cost base will be tightly managed to deliver expected earnings.

The following items are excluded from net income/(loss) from continuing operations in calculating both 2008 and 2009 Non GAAP diluted earnings:

- Intangible asset amortization and impairment charges;

- Gains and losses on the sale of non-core assets;

- Upfront payments and milestones in respect of in-licensed and acquired

products (including the 2008 payment to Zymenex A/S ("Zymenex") for

METAZYM of $135 million);

- Termination costs (including the 2008 intangible asset impairment

charges, write downs and exit costs of $150m associated with

DYNEPO(R));

- Costs associated with the introduction of the new holding company;

- Costs associated with the acquisition and integration of companies, and

acquired in-process research and development charges (including Jerini

in Q3 2008);

- Other than temporary impairment of investments (including $54 million

impairment in Q3 2008); and

- Taxes associated with these items.

Depreciation, which is included in cost of product sales, R&D costs and selling, general and administrative costs in our GAAP results, has been separately disclosed for the presentation of 2008 Non GAAP earnings (see pages 24 to 28).

Product Highlights

New Product Launches - subject to obtaining the relevant regulatory/governmental approvals, product launches planned over the next two years include:

- MEZAVANT(R) (mesalazine) for u
'/>"/>

SOURCE Shire Plc Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
2. PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery
3. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
4. GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
5. Consumers Looking to Sustainable Food Production to Feed Global Population
6. Contour Products Introduces Groundbreaking Sleep Apnea, Respiratory and Ergonomic Body Comfort Pillows at Medtrade; Self-Explanatory Products Serve Customer Needs, Expand Retailers DME Offerings
7. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
8. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
9. Ventria Expands Lactoferrin Production
10. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
11. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space